bioMérieux’s mission is to contribute to the improvement of public health worldwide through in vitro diagnostics. Throughout its history, our company has committed to four priorities, which today, represent its strength:

• Our independence and expertise in the field of in vitro diagnostics allow us to respond rapidly in today’s complex environment and to form partnerships that are vital to our scientific and international growth.
• Our international scope, with 84% of sales coming from outside of France. Established in 150 countries, with 39 subsidiaries and an extensive network of distributors, we are close to our customers, wherever they may be, and provide a line of products tailored to the realities of each region.
• 45 years of experience and know-how in the field of infectious diseases allows bioMérieux, a world leader in microbiology, to respond to major public health issues, and affirm its position as a key player in clinical diagnostics and industrial microbiological quality control.
• Scientific and technological innovation is at the heart of the bioMérieux strategy. It has enabled us to extend our expertise to the fields of cancer and cardiovascular diseases, complementing that of infectious diseases. bioMérieux dedicates considerable resources to R&D (over 12% of its sales), pursuing an ambitious policy based on multidisciplinary internal teams and a network of international partnerships and scientific affiliations.
• bioMérieux is part of the Mérieux Alliance group, the mission of which is to provide health professionals with innovative solutions, derived from biology, and spanning the range of healthcare: prevention, diagnosis, prognosis, immunotherapy and clinical follow-up.
• bioMérieux is committed to serving a medicine that is continually more reactive, preventive and personalized in order to improve the quality of patient care. This is why our teams are located all over the world. They are at work developing diagnostic systems and reagents that respond perfectly to the demands of physicians and biologists, while anticipating scientific and technological developments. We also rely on the support of our shareholders, partners in our development, who through their continued confidence, allow us to envision the diagnostics of tomorrow.